CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach-Reference-Cited by-同舟云学术

CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach

Published:2017-12-28 Issue:3 Volume:144 Page:559-569
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Schmalenberg Harald,Al-Batran Salah-Eddin,Pauligk Claudia,Zander Thomas,Reichart Alexander,Lindig Udo,Kleiß Mathias,Müller Lothar,Bolling Claus,Seufferlein Thomas,Reichardt Peter,Kullmann Frank,Eschenburg Henning,Schmittel Alexander,Egger Matthias,Block Andreas,Goetze Thorsten Oliver

Funder

Sanofi-Aventis Germany

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/article/10.1007/s00432-017-2565-5/fulltext.html

Reference28 articles.

1. Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, Jager E (2008a) Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a Phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 19(11):1882–1887. https://doi.org/10.1093/annonc/mdn403

2. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Jager E (2008b) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26(9):1435–1442. https://doi.org/10.1200/jco.2007.13.9378

3. Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Tannapfel A (2016) Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 17(12):1697–1708. https://doi.org/10.1016/s1470-2045(16)30531-9

4. Chun JH, Kim HK, Lee JS, Choi JY, Lee HG, Yoon SM, Choi IJ, Ryu KW, Kim YW, Bae JM (2004) Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Onco 34(1):8–13

5. Cisternino S, Bourasset F, Archimbaud Y, Semiond D, Sanderink G, Scherrmann JM (2003) Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br J Pharmacol 138(7):1367–1375. https://doi.org/10.1038/sj.bjp.0705150

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular mechanisms associated with chemoresistance in esophageal cancer;Cellular and Molecular Life Sciences;2022-02

2. A narrative review: depth of response as a predictor of the long-term outcomes for solid tumors;Translational Cancer Research;2021-02

3. Cabazitaxel - A Treatment Option in Recurrent Platinum-resistant Ovarian Cancer;Anticancer Research;2020-09

4. Co-operative groups in the development of chemotherapy for gastric cancer;Japanese Journal of Clinical Oncology;2018-12-01